|
Welcome,
Guest
|
TOPIC:
Bristol-Myers Squibb targeting fibrosis research 6 years 2 months ago #22788
|
Bristol-Myers Squibb appear to be putting some focus on the anti-fibrosis field including investing in licencing rights for development of a promising new drug/delivery system (ND-L02-s0201) that targets HCV and Nash fibrosis.
hepatitiscnewdrugs.blogspot.com.au/2016/...signs-exclusive.html in.reuters.com/article/us-bristol-myers-...%2F+IN+%2F+Health%29 liverlearning.aasld.org/aasld/2015/theli.../110677/[[$item.link G3a since '78 - Dx '12 - F4 (2xHCC)
24wk Tx - PEG/Riba/Dac 2013 relapsed 24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed 16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof SVR7 - 22/06/17 UND SRV12 - 27/07/17 UND SVR24 - 26/10/17 UND  |
|
|
Please Log in or Create an account to join the conversation. |
Time to create page: 0.050 seconds
